Show simple item record

dc.contributor.authorRobles Vera, Iñaki 
dc.contributor.authorde la Visitación, Néstor
dc.contributor.authorSánchez, Manuel
dc.contributor.authorGómez Guzmán, Manuel 
dc.contributor.authorJiménez Moleón, Rosario 
dc.contributor.authorMoleón Moya, Javier 
dc.contributor.authorGonzález Correa, Cristina 
dc.contributor.authorRomero Pérez, Miguel 
dc.contributor.authorDuarte Pérez, Juan Manuel
dc.identifier.citationGarcía-García, G., Fernández-Álvarez, F., Cabeza, L., Delgado, Á. V., Melguizo, C., Prados, J. C., & Arias, J. L. (2020). Gemcitabine-Loaded Magnetically Responsive Poly (ε-caprolactone) Nanoparticles against Breast Cancer. Polymers, 12(12), 2790. [doi:10.3390/antiox9121199]es_ES
dc.description.abstractMicrobiota is involved in the host blood pressure (BP) regulation. The immunosuppressive drug mofetil mycophenolate (MMF) ameliorates hypertension. The present study analyzed whether MMF improves dysbiosis in mineralocorticoid-induced hypertension. MaleWistar rats were assigned to three groups: untreated (CTR), deoxycorticosterone acetate (DOCA)-salt, and DOCA treated with MMF for 4 weeks. MMF treatment reduced systolic BP, improved endothelial dysfunction, and reduced oxidative stress and inflammation in aorta. A clear separation in the gut bacterial community between CTR andDOCAgroups was found, whereas the cluster belonging toDOCA-MMF group was found to be intermixed. No changes were found at the phylum level among all experimental groups. MMF restored the elevation in lactate-producing bacteria found in DOCA-salt joined to an increase in the acetate-producing bacteria. MMF restored the percentage of anaerobic bacteria in the DOCA-salt group to values similar to control rats. The improvement of gut dysbiosis was associated with an enhanced colonic integrity and a decreased sympathetic drive in the gut. MMF inhibited neuroinflammation in the paraventricular nuclei in the hypothalamus. This study demonstrates for the first time that MMF reduces gut dysbiosis in DOCA-salt hypertension models. This e ect seems to be related to its capacity to improve gut integrity due to reduced sympathetic drive in the gut associated with reduced brain neuroinflammation.es_ES
dc.description.sponsorshipComisión Interministerial de Ciencia y Tecnología, Ministerio de Economía y competitividad SAF2017-84894-Res_ES
dc.description.sponsorshipJunta de Andalucía CTS-164es_ES
dc.description.sponsorshipEuropean Union (EU)es_ES
dc.description.sponsorshipMinisterio de Economía y Competitividad, Instituto de Salud Carlos III (CIBER-CV), Spaines_ES
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Heart Lung & Blood Institute (NHLBI) HL102033es_ES
dc.description.sponsorshipEuropean Union (Fondo Europeo de Desarrollo Regional, FEDER, "FEDER una manera de hacer Europa")es_ES
dc.rightsAtribución 3.0 España*
dc.subjectGut dysbiosises_ES
dc.subjectHypertension es_ES
dc.subjectOxidative stress es_ES
dc.subjectInflammation es_ES
dc.subject(Deoxycorticosterone acetate) DOCA-salt modeles_ES
dc.titleMycophenolate Improves Brain–Gut Axis Inducing Remodeling of Gut Microbiota in DOCA-Salt Hypertensive Ratses_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España